Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

Paul, E.; Konidaris, Gerasimos; Cope, Shannon; Chen, Chieh-I; Keeping, Sam; Xu, Yu; Atsou, Kokuvi; Ayers, Dieter; Guyot, Patricia; Sasané, Medha; Mojebi, Ali; Kuznik, Andreas

doi:10.18553/jmcp.2021.21164

Cited by 5 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choices of statistical distributions and correlations in probabilistic sensitivity analyses should be fully documented and justified [ 9 ]. Scenario analyses are also recommended where possible since several CUAs conducted these practices [ 34 , 56 – 62 ].…”

Section: Discussionmentioning

confidence: 99%

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Dai

Chang

et al. 2023

PharmacoEconomics

View full text Add to dashboard Cite

Background The disutilities of adverse events (AEs) are important inputs for cost-utility analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology assessment institutions and scholars have proposed recommendations for applying disutility values in economic evaluations. Objectives This study aimed to identify the current use of disutilities of AEs as model parameters in the CUA of cancer drug therapy and to compare the discrepancies between the use of disutilities and published recommendations. Methods A systematic search was conducted on the PubMed, Web of Science, and Cochrane Library databases, as well as the official websites of the National Institute for Health and Care Research (NIHR), the Institute for Clinical and Economic Review (ICER), the Institute for Quality and Efficiency in Health Care (IQWiG), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Centre for Reviews and Dissemination (CRD) for CUAs of drug therapy for cancer published in English from January 2019 to April 2022. Information about the use of disutilities of AEs (whether and how disutilities were used, or why they were not used) in selected studies was extracted and compared with published recommendations. Descriptive analyses were used to summarize the results. Results A total of 467 CUAs were included, 54% (254/467) of which included disutilities of AEs in their model. The proportion that included these disutilities increased from 2019 to 2021, ranging from 47% (51/107) to 61% (116/190). Only 6% (15/254) of the CUAs using disutilities of AEs considered all five recommendations about the justification for inclusion and exclusion, description of values and sources, grades of AEs, calculation, and uncertainty analyses. Only 15% (72/467) provided a clear justification for inclusion and exclusion of disutilities of AEs, and 7% (17/254) did not provide values or sources. In total, 69% (175/254) of the analyses focused on AEs of grade 3 or greater, and 11% (28/254) applied utility decrements for grades 1 and 2. Disutilities of AEs were generally calculated using the incidence rates, which were clearly stated in 49% (65/132) of the analyses. Uncertainty analyses were conducted in 84% (214/254) of the CUAs. Conclusions The current use of disutilities of AEs in CUAs shows some discrepancies with recommendations proposed in the literature. One is that detailed information about the use of disutilities of AEs was not reported and the other is that essential methods to analyze the impact of AEs on quality-adjusted life-years were not thoroughly conducted. Therefore, it is suggested that researchers should attach importance to the impact of AEs on health-related quality of life. Furthermore, an application process was developed for the disutilities of AEs to remind and guide researchers to correctly use the disutilities of AEs as parameters in the decision-analytic model...

show abstract

Section: Discussionmentioning

confidence: 99%

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Dai

Chang

et al. 2023

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…The antiprogrammed death ligand 1 (PD‐1) drug Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) for CSCC treatment. 3 Another anti‐PD‐1 antibody drug Libtayo (Cemiplimab‐rwlc) has shown good efficacy in the treatment of skin squamous cell carcinoma 4 ; thus the FDA has approved Libtayo for metastatic CSCC that is not suitable for surgery or radiotherapy. 5 The results of its phase II clinical trial showed that 34% of patients receiving immunotherapy have been significantly improved.…”

Section: Introductionmentioning

confidence: 99%

T‐box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1

Wang

Sun

2022

Skin Research and Technology

View full text Add to dashboard Cite

Background Cutaneous squamous cell carcinoma (CSCC) is the second largest nonmelanoma skin cancer in humans; effective treatment options for metastatic CSCC are still in short. In this study, we aimed to explore the function of T‐box transcription factor 2 (TBX2) in CSCC. Methods The expression level of TBX2 was determined in CSCC samples and cell lines. Programmed death ligand 1 (PD‐L1) expression was also analyzed in human CSCC samples. Furthermore, SCC13 cells were transfected with TBX2‐DN (loss of function) or normal TBX2 to check its role in regulating PD‐L1. Results The expression level of TBX2 was positively correlated with the stage of CSCC. CSCC tumor cell lines have significantly higher expression levels of TBX2 than normal skin cell lines, and SCC13 cells showed the highest expression. PD‐L1 expressions were upregulated during the progression of CSCC, and positively correlated with TBX2. Furthermore, PD‐L1 expression increased in SCC13 cells overexpressing TBX2. However, TBX2 did not regulate the activation of IFNγ signal, but mediated the expression of interferon regulatory factor 1 (IRF1) and PD‐L1 in both SCC13 and PDV cells. Conclusion TBX2 could mediate antitumor immune response in CSCC by regulating the expression of PD‐L1 through IRF1. It might be a prognostic marker in CSCC and synergistic target for PD‐1 immunotherapy.

show abstract

Bilateral primary squamous cell carcinoma of the conjunctiva

Bhambra¹,

Arthurs²,

Bergeron³

et al. 2022

Canadian Journal of Ophthalmology

View full text Add to dashboard Cite

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

Cited by 5 publications

References 50 publications

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

T‐box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1

Bilateral primary squamous cell carcinoma of the conjunctiva

Contact Info

Product

Resources

About